Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Japan MFN impact
(Shutterstock/AI-generated)

The ongoing uncertainties around US biopharmaceutical-related policies under President Donald Trump, including possible pharma trade tariffs and most favored nation (MFN) pricing, may present new opportunities for positive reforms in the Japanese market, say a number of expert observers in the country.

While they have mixed opinions on the US policies, the final form of which still remains unclear, the commentaries share...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Reimbursement

More from Market Access